NeoCura and PhoreMost Announce Research Collaboration to Explore Novel Cancer Therapeutics

11th January 2022

Shenzhen, China and Cambridge, UK, 11 January, 2022: NeoCura Bio-Medical Technology Co., Ltd. (“NeoCura”), a leading RNA-based drug research and development company in China, and PhoreMost Limited (PhoreMost), the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’, today announced an oncology drug discovery research collaboration.

As part of the collaboration, PhoreMost's SITESEEKER® phenotypic screening platform and NeoCura's full-process RNA drug design platform will be used to investigate the cellular delivery and efficacy of encoded targeted peptides. In this way, the research aims to inform and advance the research and development of innovative anti-cancer therapies.

PhoreMost’s SITESEEKER platform can identify the best new therapeutic targets for any chosen disease setting, and rapidly identify how to develop novel drugs to these targets. This has the potential to significantly increase the diversity of novel treatments for cancer and other unmet diseases. Based on proprietary protein interference, or ‘PROTEINi®’, technology, PhoreMost uses SITESEEKER to probe the entire proteome in a live cell environment for novel druggable targets linked to any chosen disease. This enables the systematic discovery of functionally active peptides which are directly linked to useful therapeutic applications. NeoCura has world-class RNA technology, which can significantly increase the expression efficiency of RNA cargo and improve its in vivo delivery to target tissues.

NeoCura is pleased to establish a collaborative partnership with PhoreMost. We are deeply impressed by PhoreMost's excellent protein interference technology platform and unique target mining capabilities. It is believed that with the leading RNA drug research and development capability of NeoCura and cutting-edge SITESEEKER technology of PhoreMost, more therapeutic potential will be released in the field of research and development of RNA drugs, and the translational process of anti-cancer drugs will be greatly accelerated. Meanwhile, NeoCura also hopes to join hands with more industry leaders in the vigorous development of biomedicine in China.
Dr Wang Yi, Founder and CEO of NeoCura, said

This partnership demonstrates the versatility of PhoreMost’s SITESEEKER platform, and the range of innovative drug discovery programs it can work within. NeoCura’s platform complements PhoreMost’s capabilities to unmask cryptic druggable sites across the entire human proteome. RNA delivery of novel therapeutics represents an exciting opportunity for PhoreMost as we aim to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases.
Dr Chris Torrance, CEO, PhoreMost, said


Media enquiries

Zyme Communications:
Lily Jeffery
lily.jeffery@zymecommunications.com
Phone: +44 (0)7891 477 378

At PhoreMost Ltd:
Dr Neil Torbett, CEO
neil.torbett@phoremost.com
Phone: +44 (0)1223 856 740

NeoCura
Media queries
Yan Li, Brand Communication Director
E-mail: pr@neocura.net
Tel: +86 10 8076 6127

BD and Investors
Whitney Wang, BD VP
E-mail: bd@neocura.net
Web: neocura.com.cn